2 1 Shi Ji Jing Ji Bao Dao·2025-12-03 00:13Policy Trends - In 2024, the total number of medical consultations in China reached 10.15 billion, an increase of 600 million from the previous year, with a life expectancy of 79.0 years and a maternal mortality rate of 14.3 per 100,000 [1] - The total number of medical institutions in China reached 1,093,551 by the end of 2024, an increase of 22,766 from the previous year, including 38,710 hospitals [1] - The number of health technicians in China reached 13.02 million, an increase of 531,000 (4.3%) from the previous year, with 9.37 million working in hospitals [1] Healthcare Costs - The average hospitalization cost in hospitals for 2024 was 9,870 yuan, a decrease of 4.3% from the previous year, while the average outpatient cost was 361 yuan, down 0.2% [2] - The total healthcare expenditure in China for 2024 was approximately 9,089.55 billion yuan, with government spending accounting for 24.9%, social spending for 47.6%, and personal spending for 27.5% [2] - The per capita healthcare expenditure was 6,454.4 yuan, with total healthcare expenditure constituting 6.7% of GDP [2] Pharmaceutical Developments - The National Medical Insurance Administration launched a drug price registration and inquiry service, allowing pharmaceutical companies to self-declare drug prices for public access [3] - Renfu Pharmaceutical announced the withdrawal of its application for the registration of a recombinant plasmid-hepatocyte growth factor injection, which had a cumulative R&D investment of approximately 160 million yuan [4] - Hengrui Medicine received acceptance for its application for the marketing authorization of remimazolam tosylate for sedation during mechanical ventilation in intensive care [4] Investment Activities - China Resources Sanjiu established a biopharmaceutical fund in Hohhot with a total investment of 500 million yuan, focusing on private equity investments and asset management [5] - Zhaoli Pharmaceutical plans to raise up to 1.556 billion yuan through convertible bonds for the development of an intelligent traditional Chinese medicine health factory and other projects [6] Global Health Issues - The World Health Organization reported that reductions in international aid are impacting global HIV prevention efforts, with significant challenges ahead for AIDS response programs [7] Regulatory Actions - Jiangsu Wuzhong received a delisting notice from the Shanghai Stock Exchange due to major violations, including concealing changes in actual control and severe financial fraud [8] - The company is set to enter a delisting transition period on December 9, 2025, with the last trading day expected to be December 29 [8]